BranimirI.SikicMD

Oncology • Stanford, CA

Professor, Medicine - Oncology, Stanford University Medical Center

Join to view full profile

Dr. Sikic is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sikic's full profile

Already have an account?

Office
300 Pasteur Dr
Stanford, CA 94305
Phone+1 650-723-4000

Fax+1 650-498-5840

Summary

Dr. Branimir Sikic is an oncologist at Stanford University. He received his medical degree from University of Chicago Pritzker School of Medicine and was in practice 45 years. He is experienced in ovarian neoplasms and adenocarcinoma. He has more than 250 publications and over 10,000 citings.

Education & Training

Georgetown University HospitalFellowship, Medical Oncology, 1977 - 1979
National Institutes of Health Clinical CenterFellowship, Medical Oncology, 1973 - 1975
MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 1972 - 1975
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1972

Certifications & Licensure

CA State Medical License 1979 - 2023
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Fellow (FASCO) American Society of Clinical Oncologists, 2010

Clinical Trials

Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal Cancer Start of enrollment: 2001 Jul 01
Completed
Phase 2
Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma Start of enrollment: 2003 Mar 01
Terminated
Phase 1
A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer Start of enrollment: 2004 Jun 01
Terminated
Phase 1, Phase 2
Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer Start of enrollment: 2006 Jul 01
Completed
Phase 1
Genome, Proteome and Tissue Microarray in Childhood Acute Leukemia Start of enrollment: 2001 Jul 01
Terminated
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers Start of enrollment: 2011 Oct 01
Completed
Phase 1
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma Start of enrollment: 2013 Jul 12
Completed
Phase 3
Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody Start of enrollment: 2014 Aug 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

5596 citations
Integrated genomic analyses of ovarian carcinoma
Debra A. Bell, Andrew Berchuck, Michael J. Birrer, Jeremy Chien, Daniel W. Cramer
Nature. 2011-06-30
88 citations
Differential Gene Expression Patterns and Interaction Networks in BCR-ABL–Positive and –Negative Adult Acute Lymphoblastic Leukemias
Dejan Juric, Norman J. Lacayo, Meghan Ramsey, Janis Racevskis, Peter H. Wiernik
Journal of Clinical Oncology. 2007-04-10
93 citations
Multidrug resistance in lymphomas.
Alan R. Yuen, Branimir I. Sikic
Journal of Clinical Oncology. 1994-11-01

Lectures

A first-in-class, first-in-human phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of Hu5F9-G4, an anti-CD47 monoclonal antibody (mAb), in patients with adva...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Anti-CD47 Antibody Trial in Advanced Cancers Shows Treatment Appears Safe, Well-ToleratedMarch 5th, 2019

Grant Support

Protocol Specific Research SupportNational Cancer Institute2010–2011
Taxane Resistance In Breast And Ovarian Cancer CellsNational Cancer Institute2007–2011
Study Of Oblimersen (Genasensetm, G3139) In Advanced MalignanciesNational Center For Research Resources2006
Treatment Of Advanced Solid MalignanciesNational Center For Research Resources2005
Study Of Oblimersen In Combination With Gemcitabine In Advanced MalignanciesNational Center For Research Resources2005
Regulation Of The Human MDR1 GeneNational Cancer Institute2002–2005
Phase I Study: Weekly Bms-188797 Alone &With CarboplatNational Center For Research Resources2004
Phase I Study Of Bms-310705 Given Every Three WeeksNational Center For Research Resources2004
A Phase I Study Of ZD1839 (Iressa Tm) With OxaliplatinNational Center For Research Resources2004
A Phase I Study Of Oblimersen (Genasense TM, G3139)National Center For Research Resources2004
Gene Expression Profiling Of Unknown Primary CancersNational Cancer Institute2001–2003
Modulation Of Multidrug Resistance MechanismsNational Cancer Institute1999–2002
Phase I Trial Of Oral Paclitaxel And Valspodar (Psc 833)National Center For Research Resources2000–2001
Phase I Trial Of Doxil, Paclitaxel And Valspodar PSC 833National Center For Research Resources2000–2001
Ly335979 &Mitoxantrone In Prostate CancerNational Center For Research Resources2000–2001
Phase I Trial Of Antisense Inhibitor Of Protein Kinase C Alpha In CanNational Center For Research Resources1999–2001
Phase II Of ISIS 3521 In Patients With Ovarian CarcinomaNational Center For Research Resources1998–2001
Phase I Protein Kinase, Carboplatin And Paclitaxel Chemo. For CancerNational Center For Research Resources1998–2001
Paclitaxel And PSC 833 In Metastatic Colorectal CarcinomaNational Center For Research Resources1998–2001
Phase I Trial Of Doxorubicin, Paclitaxel, And PSC 833National Center For Research Resources1997–2001
CGP 64128a Administered As A Continuous Infusion In Patients With CancerNational Center For Research Resources1998–1999
Tubulin Genes And Drug ResistanceNational Cancer Institute1996–1998
Expression And Modulation Of Multidrug ResistanceNational Cancer Institute1990–1998
Phase II Clinical Trial Of Paclitaxel &Psc 833 In Metastatic Colorectal CancerNational Center For Research Resources1997
Phase I Clinical Trial Of Cgp64128a Administered As A Continuous InfusionNational Center For Research Resources1997
Trial Of Doxorubicin, Paclitaxel, And PSC 833National Center For Research Resources1996
Phase 1 Trial Of Taxol And PSC-833 ChemotherapyNational Center For Research Resources1996
Cyano-Morpholino AnthracyclinesNational Cancer Institute1986–1988